IL262526B - Dipeptidyl peptidase 4 inhibitors for local treatment of neurodegenerative retinal diseases - Google Patents
Dipeptidyl peptidase 4 inhibitors for local treatment of neurodegenerative retinal diseasesInfo
- Publication number
- IL262526B IL262526B IL262526A IL26252618A IL262526B IL 262526 B IL262526 B IL 262526B IL 262526 A IL262526 A IL 262526A IL 26252618 A IL26252618 A IL 26252618A IL 262526 B IL262526 B IL 262526B
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- neurodegenerative diseases
- dipeptidyl peptidase
- eye treatment
- topical eye
- Prior art date
Links
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000002207 retinal effect Effects 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382190 | 2016-04-29 | ||
| PCT/EP2017/060234 WO2017186934A1 (en) | 2016-04-29 | 2017-04-28 | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL262526A IL262526A (en) | 2018-12-31 |
| IL262526B true IL262526B (en) | 2022-05-01 |
Family
ID=55953092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL262526A IL262526B (en) | 2016-04-29 | 2018-10-22 | Dipeptidyl peptidase 4 inhibitors for local treatment of neurodegenerative retinal diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11013738B2 (enExample) |
| EP (1) | EP3448388B1 (enExample) |
| JP (1) | JP7068706B2 (enExample) |
| KR (1) | KR102411574B1 (enExample) |
| CN (1) | CN109152776B (enExample) |
| AU (1) | AU2017256803B2 (enExample) |
| BR (1) | BR112018072127A2 (enExample) |
| CA (1) | CA3022152C (enExample) |
| DK (1) | DK3448388T3 (enExample) |
| ES (1) | ES2863701T3 (enExample) |
| IL (1) | IL262526B (enExample) |
| MX (1) | MX383599B (enExample) |
| RU (1) | RU2744878C2 (enExample) |
| WO (1) | WO2017186934A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017186934A1 (en) * | 2016-04-29 | 2017-11-02 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases |
| RU2727898C1 (ru) * | 2020-02-25 | 2020-07-24 | Общество с ограниченной ответственностью «Необиотек» | Фармацевтическая композиция на основе действующего вещества, ингибитора дипептидилпептидазы-4, для предупреждения развития и лечения сахарного диабета 2 типа |
| CN111166870A (zh) * | 2020-03-18 | 2020-05-19 | 复旦大学附属眼耳鼻喉科医院 | 艾塞那肽在制备滴眼治疗眼部缺血疾病、改善眼部血液循环的药物中的应用 |
| GB202014740D0 (en) * | 2020-09-18 | 2020-11-04 | Invex Therapeutics Ltd | Method of reducing intraocular pressure |
| WO2026078034A1 (en) | 2024-10-09 | 2026-04-16 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Sitagliptin for use in retinal diseases with neovascularization |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122010000020I1 (de) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| EP1940388A2 (en) * | 2005-09-30 | 2008-07-09 | Novartis AG | Dpp iv inhibtor for use in the treatment of autoimmune diseases and graft rejection |
| US7560597B2 (en) * | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| WO2009084024A2 (en) * | 2007-11-02 | 2009-07-09 | Glenmark Generics Limited | A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof |
| EP2249643A4 (en) * | 2008-02-05 | 2013-10-09 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE IV HEMMER |
| EP2251028A1 (en) * | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| CN101921270A (zh) * | 2009-06-16 | 2010-12-22 | 海南德泽药物研究有限公司 | 一种芒果苷小檗碱盐及其制备方法与用途 |
| TWI469785B (zh) * | 2012-04-25 | 2015-01-21 | Inovobiologic Inc | 用於治療代謝性疾病之膳食纖維組成物 |
| JP6368722B2 (ja) * | 2013-03-01 | 2018-08-01 | フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ | 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド |
| KR102238860B1 (ko) * | 2013-06-14 | 2021-04-12 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 및 이의 합병증의 치료를 위한 dpp-4 억제제 |
| WO2017186934A1 (en) * | 2016-04-29 | 2017-11-02 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases |
-
2017
- 2017-04-28 WO PCT/EP2017/060234 patent/WO2017186934A1/en not_active Ceased
- 2017-04-28 JP JP2018555725A patent/JP7068706B2/ja active Active
- 2017-04-28 MX MX2018013022A patent/MX383599B/es unknown
- 2017-04-28 US US16/095,621 patent/US11013738B2/en active Active
- 2017-04-28 RU RU2018140127A patent/RU2744878C2/ru active
- 2017-04-28 BR BR112018072127-1A patent/BR112018072127A2/pt not_active Application Discontinuation
- 2017-04-28 CN CN201780030017.3A patent/CN109152776B/zh active Active
- 2017-04-28 KR KR1020187033209A patent/KR102411574B1/ko active Active
- 2017-04-28 AU AU2017256803A patent/AU2017256803B2/en active Active
- 2017-04-28 EP EP17722716.2A patent/EP3448388B1/en active Active
- 2017-04-28 ES ES17722716T patent/ES2863701T3/es active Active
- 2017-04-28 DK DK17722716.2T patent/DK3448388T3/da active
- 2017-04-28 CA CA3022152A patent/CA3022152C/en active Active
-
2018
- 2018-10-22 IL IL262526A patent/IL262526B/en unknown
-
2021
- 2021-04-29 US US17/244,889 patent/US11918577B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018072127A2 (pt) | 2019-03-19 |
| IL262526A (en) | 2018-12-31 |
| CA3022152A1 (en) | 2017-11-02 |
| US20190134030A1 (en) | 2019-05-09 |
| WO2017186934A1 (en) | 2017-11-02 |
| JP2019519479A (ja) | 2019-07-11 |
| RU2744878C2 (ru) | 2021-03-16 |
| AU2017256803B2 (en) | 2022-12-01 |
| CN109152776B (zh) | 2022-04-29 |
| CN109152776A (zh) | 2019-01-04 |
| US20210315890A1 (en) | 2021-10-14 |
| AU2017256803A1 (en) | 2018-12-06 |
| EP3448388B1 (en) | 2020-11-18 |
| ES2863701T3 (es) | 2021-10-11 |
| KR20190003575A (ko) | 2019-01-09 |
| CA3022152C (en) | 2024-10-29 |
| KR102411574B1 (ko) | 2022-06-21 |
| RU2018140127A3 (enExample) | 2020-07-02 |
| JP7068706B2 (ja) | 2022-05-17 |
| EP3448388A1 (en) | 2019-03-06 |
| US11918577B2 (en) | 2024-03-05 |
| RU2018140127A (ru) | 2020-05-29 |
| DK3448388T3 (da) | 2021-02-08 |
| MX383599B (es) | 2025-03-14 |
| US11013738B2 (en) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL248732B (en) | Compounds for the treatment of ophthalmological diseases and disorders | |
| IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
| IL253244A0 (en) | Methods for treating retinal diseases | |
| SMT201900370T1 (it) | Agenti terapeutici per malattie neurodegeneravite | |
| LT3122878T (lt) | Terapija mrnr, skirta akių ligų gydymui | |
| IL264048A (en) | pde9 inhibitors for the treatment of peripheral diseases | |
| HUE066769T2 (hu) | Neurodegeneratív szembetegség kezelése pridopidinnal | |
| SI3548061T1 (sl) | Zdravljanje nevroloških bolezni | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| EP3340974A4 (en) | METHODS OF TREATING DISEASES | |
| IL273929A (en) | Therapeutic agents for neurodegenerative diseases | |
| EP3200828A4 (en) | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders | |
| IL259153A (en) | Use of proteasome inhibitors to treat ocular disorders | |
| DK3448388T3 (da) | Dipeptidyl-peptidase-4-inhibitorer til topikal øjenbehandling af retinale neurodegenerative sygdomme | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| PL3689341T3 (pl) | Gabapentyna okulistyczna do leczenia deepitelializacji rogówki | |
| EP3534954A4 (en) | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| GB201704666D0 (en) | Treatment of neurodegenerative diseases | |
| HK40006877A (en) | Pde9 inhibitors for treatment of peripheral diseases | |
| AU2014903944A0 (en) | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |